Edwards Lifesciences’ CFO Ullem sells $1m in shares

CFO Scott B. Ullem sold 13,000 shares on Apr 9, 2026 for $1,040,544 and concurrently exercised options to acquire 13,000 shares at $59.2567 (total cost $770,337), leaving him with 39,699 direct and 266,318 indirect shares. Edwards reported Q4 2025 adjusted EPS $0.58 vs $0.62 expected (miss) and revenue $1.57B vs $1.55B expected, +11.6% YoY; company trades at a P/E of 44 and market cap ~$45.6B. Two‑year TRISCEND II trial data showed lower all‑cause mortality and improved quality of life for the EVOQUE device, Stifel reiterated Buy with $110 PT, and InvestingPro flags the stock as trading below its fair value with 21 analysts revising earnings higher.

Analysis

Edwards sits at an inflection where clinical trial momentum (new TTVR data) and a global access push can meaningfully re-rate the stock over 12–36 months if procedural adoption follows the TAVR curve; the real value swing will be driven less by near-term quarters and more by hospital capital cycles, reimbursement wins, and incremental penetration of non-traditional centers. Second-order winners include catheter/component suppliers and imaging vendors that scale with higher structural-case volumes; conversely, competitors with broader electrophysiology footprints could see slower relative growth if structural heart captures disproportionate OR/cath lab capacity.

Key tail risks are payer/regulatory friction and hospital capex constraints that can stall a technically successful device’s commercial ramp — these are 6–24 month gating items that can flip a positive clinical narrative into elongated cash flow timelines. Near-term market moves will be sensitive to visibility events (guidance, CMS local coverage decisions, peripheral trial readouts) while medium-term outcomes hinge on durable real-world safety signals and margin expansion from manufacturing scale.

Consensus optimism appears to crowd the “clinical win = linear sales” path and under-weights adoption frictions; that makes a constructive but hedged approach attractive. If pricing and reimbursement follow best-case assumptions, multiple expansion is realistic; if they don’t, the valuation compresses quickly because growth is execution- and policy-dependent. Use event-driven sizing: lean into multi-year optionality with capped-cost option structures or through relative-value pairings to extract pure device-adoption upside while limiting binary outcome risk.

Key Decisions for Investors

• Long EW equity (6–18 months): accumulate on pullbacks toward ~10–20% below current levels as a core position to capture TAM expansion from TTVR adoption; size to no more than 2–3% portfolio and hedge with a 9–12 month out-of-the-money (OTM) put to cap downside — target 30–50% upside if adoption and reimbursement track consensus.
• Call spread (12 months): buy EW 12-month at-the-money calls and sell 20–30% OTM calls to fund premium — asymmetric upside if clinical adoption accelerates with defined max loss = premium paid, target >200% return if multiple expansion occurs.
• Pair trade (6–18 months): long EW / short MDT (equal notional) to isolate structural-heart adoption upside versus diversified device execution risk; this reduces market-beta and profits if Edwards’ valve franchise re-rates faster than Medtronic’s broader portfolio. Monitor competitor trial/regulatory moves weekly and rebalance on major readouts.
• Event hedge (0–3 months): buy short-dated EW puts or a collar into the next guidance/coverage milestone to protect against a negative reimbursement or guidance reset — limit cost by selling short-dated calls if comfortable capping upside in the near term.